Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men’s Health Categories IRVING, Texas --(BUSINESS WIRE)--Aug. 10, 2023-- Biote (NASDAQ: BTMD), a leading solutions

IRVING, Texas --(BUSINESS WIRE)--Jul. 27, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide second quarter financial results on Thursday, August 10, 2023 , after the close of the market.

Leader in Hormone Education and Training Aims to Increase Awareness and Access to Testosterone Deficiency Therapy through Expanded Network of Urologists and Internal Medicine Practitioners IRVING, Texas --(BUSINESS WIRE)--Jun. 22, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a

IRVING, Texas --(BUSINESS WIRE)--Jun. 8, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced (i) offer to each

IRVING, Texas --(BUSINESS WIRE)--Jun. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten offering of 5,217,392 shares of its Class A common

IRVING, Texas --(BUSINESS WIRE)--May 31, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced its participation at the following investor conferences: On June 6,

Ms. Puncochar to Drive Execution of Biote’s Strategic Sales and Marketing Initiatives IRVING, Texas --(BUSINESS WIRE)--May 30, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy,

New Initiative Targets Long-term Growth Opportunity in Men’s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance IRVING, Texas --(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through

IRVING, Texas --(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent

IRVING, Texas --(BUSINESS WIRE)--Apr. 26, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023